Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

126.05 +1.90 (+1.53%)
Streaming Delayed Price Updated: 3:06 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Evaluating Jazz Pharmaceuticals: Insights From 7 Financial Analysts
Via Benzinga
2 Incredible Growth Stocks That Are Screaming Buys for 2024
These healthcare businesses are compelling buys for very different reasons. 
Via The Motley Fool
4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-fueled Nasdaq Composite remains 7% below its all-time high, which means bargains can still be found. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings Expectations
Several market-moving catalysts, including the release of the Fed minutes, a Federal Reserve speech, and JOLTS data, could influence the day's market movement. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Decoding 6 Analyst Evaluations For Jazz Pharmaceuticals
Via Benzinga
Analyst Ratings for Jazz Pharmaceuticals
Via Benzinga
Jazz Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World
If the Federal Reserve loosens the monetary spigot, these companies could represent the growth stocks to buy now. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy... 
Via Benzinga
3 No-Brainer Stocks to Buy With $500 Right Now
You don't need a mountain of cash to build wealth on Wall Street. 
Via The Motley Fool
Japan Approves Marijuana-Derived Medicines, Adopt 7-Year Prison Sentences For Recreational Use
Japan’s Parliament passed a bill Wednesday legalizing medical products derived from cannabis. 
Via Benzinga
Australian MPs Admit They Tried Cannabis, Signaling Policy Reform & Epidiolex For Seizures Approved In Canada
Around 8% of Australians are using medical marijuana either occasionally or regularly, according to a recent survey of 1,000 participants conducted by consumer insights company Antenna, reported... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
Investing in biotech stocks can be tricky, but analysts have bullish outlooks on these three, promising companies. 
Via InvestorPlace
Pot Stocks: Values Or Traps?
Pot stocks were the hottest thing around five years ago but after catching a bid during the pandemic, the stocks have now plunged to multi-year lows. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
3 Biotech Stocks That Could Be Millionaire Makers
Many biotech stocks offer exciting long-term growth prospects. 
Via The Motley Fool
Police Boss Turned Cannabis Reform Advocate, MMJ Legalization In Japan And More Global Updates
Medical Cannabis-Based Epidiolex Advances Through Japan's Legislature Earlier this week, Japanese policymakers gave the green light to a measure to legalize medical products derived from cannabis,... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 No-Brainer Stocks to Buy With $200 Right Now
A modest amount of money can go a long way when it's invested in inexpensive, game-changing businesses. 
Via The Motley Fool
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
From Autifony Therapeutics Ltd
Via Business Wire
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
Cannabis Cash Burn Concerns? Sell These 7 Overbought Stocks Now.
These overbought cannabis stocks are teetring on the edge as the sector is navigating through uncharted waters. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
FDA Report On Its 50 Years In Cannabis Research, Signals A Boost In Medical Marijuana Prospects
Researchers with the Food and Drug Administration (FDA) reported Wednesday on the agency’s 50 years of experience with marijuana research. In an article titled “FDA’s 50 
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
Ireland Reimburses Medical Marijuana-Based Drug For Chemotherapy-Induced Nausea And Vomiting
Althea Group Holdings Limited (ASX: AGH), an Australian manufacturer of cannabis-based medicines and recreational cannabis products confirmed that Ireland’s Primary Care Reimbursement... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Europe's High: UK Parents Need NHS Help For Daughter's Seizures, THC MMJ Flowers In Switzerland & More
Luxembourg: Medical Marijuana Shortage Due To Supplier Change 
Via Benzinga
Topics Cannabis Supply Chain
Exposures Cannabis Supply Chain
Cannabis Stocks Dip: How Rising Interest Rates Impact Your Portfolio
On Friday, cannabis stocks traded lower with the overall market. Marketfy analyst Michael Berger will be monitoring how the sector performs this week. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Europe's High: Irish GPs Against Pot, Switzerland-Spain Share Data On Cannabis Clubs & More
Denmark: Medical Marijuana Pilot Program Experience 90% Growth In 12 Months 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Explores Asset Sale Option, Possibly Cannabinoid Business: Report
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is reportedly exploring strategic options comprising a potential sale. 
Via Benzinga
2 Top Biotech Stocks to Buy in October
Growth catalysts lie ahead for both of these players. 
Via The Motley Fool
5 Genius Safe Stocks to Buy for the 4th Quarter of 2023
These highly profitable, time-tested companies can deliver for their shareholders in any economic climate. 
Via The Motley Fool
4 Perfect Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
An 18% decline in the Nasdaq Composite from its all-time high means bargains still abound. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.